14680-51-4CCN(CC)CCn1c(Cc2ccc(OC)cc2)nc2cc([N+](=O)[O-])ccc21HNGZTLMRQTVPBH-UHFFFAOYSA-NMetonitazene is a member of the class of benzimidazoles that is 1H-benzimidazole substituted by 2-(diethylamino)ethyl, 4-methoxybenzyl, and nitro groups at positions 1, 2, and 5, respectively. It is a synthetic opioid. It has a role as an opioid analgesic and a mu-opioid receptor agonist. It is a member of benzimidazoles, a monomethoxybenzene, a C-nitro compound and a tertiary amino compound.
DEA NFLIS-Drug Category -> Narcotic Analgesics
DEA Schedule I Controlled Substance -> Opiates
Metonitazene is classified as a novel opioid but is dissimilar from fentanyl and U-series analogues. This substance has been characterized as a white or off-white/beige powder, sometimes referred to as crystalline in consistency (Cayman Chemicals, 2020; Krotulski et al., 2021; PubChem, 2020). Both the free base and hydrochloride salt forms can appear as white or colored powders, while the citrate salt is described as a crystalline solid (Cayman, 2021a).
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
개요Metonitazene is an analgesic drug related to etonitazene and was first synthesized in the late 1950s by a Swiss chemical company in an effort to develop novel opioid alternatives to morphine. Metonitazene has been shown to have approximately 100 times the potency of morphine by central routes of administration, but if used orally it has been shown to have approximately 10 times the potency of morphine.
용도Metonitazene is an active analgesics with clinical applications.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
14680-51-4DTXSID901336445CHEBI:234362